- Home
- PLCE vs MREO Comparison
PLCE vs MREO Comparison
Compare PLCE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLCE | MREO |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 50.3M |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PLCE | MREO |
|---|---|---|
| Price | $2.20 | $0.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $3.50 | $1.50 |
| AVG Volume (30 Days) | 270.5K | ★ 1.4M |
| Earning Date | 04-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.48 | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | $4.41 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $0.20 |
| 52 Week High | $9.56 | $2.37 |
Technical Indicators
Market Signals| Indicator | PLCE | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | N/A |
| Support Level | $2.04 | N/A |
| Resistance Level | $2.88 | N/A |
| Average True Range (ATR) | 0.20 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 36.31 | 0.00 |
Price Performance
Historical ComparisonAbout PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).